Evidence map›Paper›PMID 27434290›Full record

ArticleCancer biomarkers : section A of Disease markers2016

MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.

Bing Yang, Zheng Liu, Hao Ning, Kai Zhang, Dongliang Pan, Kejia Ding, Wei Huang, Xin-Li Kang, Yang Wang, Xiang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bing YangDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Zheng LiuDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Hao NingDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Kai ZhangDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Dongliang PanDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Kejia DingDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Wei HuangDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Xin-Li KangDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Yang WangDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Xiang ChenDepartment of Urology, Shougang Hospital of Peking University, Beijing, China.
Peking University Shougang Hospital · CNShandong Provincial Hospital · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of microRNA-21 (miR-21) in peripheral blood mononuclear cells (PBMC) in the diagnosis and prognosis of prostate cancer (PCa).

methodsProved by pathologic biopsy, 92 patients diagnosed with PCa and also underwent resection operation and 85 patients with benign prostatic hyperplasia (BPH) were selected in this study, as well as 97 healthy volunteers were chosen as the control group. PBMC were extracted to examine the relative expression of miR-21 by real time reverse transcriptase-polymerase chain reaction (RT-PCR). The relative operating characteristic (ROC) curves were drew to analyze the diagnosis value of PCa. The survival function curves were made by Kaplan-Meier method to show the miR-21 expression levels of PCa patients. The Log-rank test was adopted to compare the differences among the different groups. The Cox proportional hazard risk regression analysis was used to screen the independent factors affected the PCa patients.

resultsThe expression levels of miR-21 in PCa group were increased compared to BPH and control group (P < 0.05). The expression of miR-21 was significantly correlated with the Gleason score, clinical stages, bone metastasis and tumor recurrence (all P < 0.05). ROC curves demonstrated that the area under the curve of PCa and BPH distinguished by the miR-21 were 0.974 and 95% confidence intervals (95% CI) were 0.956∼ 0.993. The sensitivity and specificity were 93.5% and 92.9%. ROC curves demonstrated that the area under the curve of PCa and control group distinguished by the miR-21 were 0.984 and 95% CI were 0.972∼ 0.997. The sensitivity and specificity were 94.6% and 92.8%. The results of Kaplan-Meier Method demonstrated that the miR-21 expression levels were related to the prognosis of PCa (all P < 0.05). The results of the COX analysis suggested that the miR-21 expression level, tumor recurrence and bone metastasis could be the independent factors affected the prognosis of PCa patients (all P < 0.05).

conclusionmiR-21 is highly expressed in the PCa patients, which could be the molecule biomarker of diagnosis and prognosis of PCa.

Indexed as

AdultAgedBiomarkers, TumorGene Expression Regulation, NeoplasticHumansLeukocytes, MononuclearMaleMicroRNAsMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProstatic HyperplasiaProstatic NeoplasmsRecurrenceROC CurveBiomarkers, TumorMicroRNAsMIRN21 microRNA, humanbenign prostatic hyperplasiabone metastasisgleason scoresMicroRNA-21peripheral blood mononuclear cellsProstate cancerspecific antigentumor recurrences

Identifiers

PMID27434290
PMCPMC13020489
OpenAlexW2467632157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.